Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic) form of the naturally occurring tissue kallikrein-1 (KLK1) protein — a critical molecular trigger for blood-vessel dilation. Stroke Indication ($10...
— Yaron Naymark
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on DIAMEDICA THERAPEUTICS INC
More institutional theses from 1 Main Capital
I recently wrote up HGV in the Q2’26 letter. When the company...
1MC has owned IWG since 2022, and it has been one of our largest holdings since 2023. We bought our...
I more than doubled 1MC’s investment in LMB after weak Q2 results caused it to decline meaningfully to a level 75% below its 2025 highs. I recently discussed...